Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
RG7795
Другие языки:

    RG7795

    Подписчиков: 0, рейтинг: 0
    RG7795
    RG-7795.svg
    Clinical data
    Other names RG-7795; ANA773; ANA-773
    Legal status
    Legal status
    • Investigational
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    Chemical and physical data
    Formula C12H14N4O5S
    Molar mass 326.33 g·mol−1
    3D model (JSmol)
    • O=C1N(C=2C(S1)=CN=C(N)N2)[C@]3([C@H](OC(C)=O)C[C@@H](CO)O3)[H]
    • InChI=1S/C12H14N4O5S/c1-5(18)20-7-2-6(4-17)21-10(7)16-9-8(22-12(16)19)3-14-11(13)15-9/h3,6-7,10,17H,2,4H2,1H3,(H2,13,14,15)/t6-,7+,10+/m0/s1
    • Key:HOOMGTNENMZAFP-NYNCVSEMSA-N

    RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. It is an orally-available prodrug of isatoribine, that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011. Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.

    Chemical structure of isatoribine

    As of 2021, development of RG7795 appears to be discontinued.


    Новое сообщение